-
Part 2 | Session 7 MK-0616: Oral PCSK9 inhibitor In Hypercholesterolemia Patients
-
Part 2 | Session 8 Evaluation of the Mechanism of Benefit for Dapagliflozin in HFpEF
-
Part 2 | Session 9 BMAD Trial: μCor in Ambulatory Decompensated Heart Failure
-
Part 3 | Session 1 ACC.23 Late-breaking Science Wrap Up
-
Part 3 | Session 2 What's Hot at ACC.23? Late-breaking Science Preview
-
Part 4 | Session 2 Lipid Management & the CLEAR Trial with Dr Erin Michos
-
Part 4 | Session 3 Obesity Management Strategies in 2023 with Dr Harold Bays
-
Part 4 | Session 4 ACC.23 President Interview with Dr B Hadley Wilson
-
Part 5 | Session 1 Dr Akowuah: Cardiovascular Research & Message for Early-Career Researchers
-
Part 5 | Session 2 Dr Kini: Asking Questions & Her Motivation to Do Research on Plaque
-
Part 5 | Session 4 Dr Verma: Passion for Electrophysiology & His Advice For Young Researchers
-
Part 5 | Session 6 Dr Hahn: Innovative Areas of Cardiovascular Science in 2023
-
Part 5 | Session 7 Dr Forrest: Structural Heart Innovations and Advice to Young Researchers
-
Part 1 | Session 1 The CLEAR-Outcomes Trial with Dr Harriette Van Spall & Dr Steven Nissen
-
Part 1 | Session 5 The BIOVASC Trial with Dr Harriette Van Spall & Prof Roberto Diletti
-
Part 2 | Session 1 Statins to Protect Heart During Cancer Treatment: The STOP-CA Trial
-
Part 2 | Session 2 RENOVATE-COMPLEX-PCI: IVUS Vs OCT Optimisation in Complex PCI
-
Part 2 | Session 3 Effect of Evolocumab on Coronary Plaque Morphology: The YELLOW III Study
We are joined onsite by Dr John Forrest (Yale Valve Clinic, US) in this short video, who outlines the three-year outcomes of the Evolut Low-Risk Trial (Medtronic Cardiovascular). This study aimed to compare transcatheter aortic valve replacement (TAVR) using Medtronic's TAVR valve with surgical aortic valve replacement (SAVR) in over 2000 patients with aortic stenosis who had low surgical risk.
TAVR had consistent benefit at 3 years compared with surgery in terms of all-cause mortality and disabling stroke.
Questions:
- What is the reasoning behind this trial?
- Please outline the patient population and study design.
- What are the main results?
- What are the implications of these findings for clinical practice?
- What further research is required?
Recorded on-site at ACC.23, New Orleans, 2023.
Our regular review series View from the Thoraxcenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) provides a critical analysis of the late-breaking and featured science results and spotlights impactful data.
For a deeper look into the key clinical trial data revealed at ACC 23, Dr Harriette Van Spall (McMaster University, Hamilton, CA) interviews the principal investigators in her regular Late-Breaker Discussion Series.
For short, concise coverage of the key data revealed, our accessible Expert Interviews were conducted with select faculty, focussing on the results, applicability and impact on future research.
More from this programme
Part 1
Late-Breaker Discussion Series
Part 2
Expert Interviews
Part 3
View from the Thoraxcenter
In these concise episodes of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offer their thoughts on the top late-breaking trials that will be presented at ACC 2023.
Part 4
Comments